Paradigm shift in drug development: Project commencement to initiation of human proof-of-concept (POC) studies in 12-24 months based on centuries of human medicinal use

Developing novel, prescription medicines derived from plants for mental health indications including cognitive deficits in attention-deficit/hyperactivity disorder (ADHD) and schizophrenia

Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.

Our Mission

Paradigm-shifting drug development approach: 12-24 months from plant collection to clinical proof-of-concept study initiation possible; higher probability for future FDA-approved botanical drugs to be safe and efficacious due to history of medicinal use

Our Goal

Novel, safe, efficacious next-generation psychoactive FDA-approved drugs developed under FDA Botanical Guidance

Our Focus

FDA-approved drugs for daily use with initial focus on:

  • Improvement of executive dysfunction in patients with ADHD

  • Improvement of cognitive deficit in schizophrenia

Our Pipeline

  • Pipeline of IND-enabled drugs for ADHD, schizophrenia, anxiety and depression

The Growing Need for Medicines Derived from Plants with Novel Mechanisms of Action (MOAs)

  • According to the World Health Organization, 1 in 4 people in the world will be affected by mental or neurological disorders at some point in their lives

  • The Lancet Commission estimates that the cost of mental disorders, currently on the rise in every country, will reach $16 trillion by 2030, including costs associated with lost productivity